Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2858)	5/9/2013 10:07:01 AM
From: Biotech Jim	Read Replies (5) \| Respond to of 3202

So the paper tells me that in some mice strains that collagen-induced arthritis (CIA) is a T cell disease. In other strains CIA is a B cell disease (Orencia data) and in even other strains it is a complement-mediated disease (see Craig Gerard work amongst others). So several mechanisms for arthritis in man based on both preclinical (in vitro cell line) data and clinical data. I would like to see the INCY IDO inhibitor in this model, as 1-methyl-DL- tryptophan is likely a micromolar inhibitor, and the INCY compound is a nanomolar inhibitor. My question to you Rick is how many oncologic situations represent T cell mediated disease wherein IDO could be downstream and thus a compelling target?